Organogenesis Holdings Inc. Class A (ORGO) Dividend History

Organogenesis Holdings Inc. Class A (ORGO) is a biotechnology company focused on developing and commercializing advanced regenerative medicine products. It specializes in tissue repair and wound management solutions derived from living cells and biological materials, aiming to improve outcomes in diverse medical fields such as surgical, wound care, and dental applications.

85 Dan Road, Canton, MA, 02021
Phone: 781-575-0775
Website:

Dividend History

Organogenesis Holdings Inc. Class A currently does not pay dividends

Company News

  • Organogenesis (ORGO) Q4 2024 Earnings Call Transcript

    Organogenesis Holdings Inc. reported strong Q4 2024 revenue growth of 27%, driven by better-than-expected customer demand. However, the company expects a challenging operating environment in the first half of 2025 due to delays in the implementation of new Medicare coverage policies for skin substitute products. The company provided financial guidance for 2025 and updated on the progress of its ReNu clinical program.

    The Motley Fool
  • Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference

    CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the Truist Securities MedTech Conference, which is being held at the InterContinental Boston in Boston, MA on Tuesday, June 18th. Management will participate in 1x1 meetings. There will be no formal presentation.

    GlobeNewswire Inc.
  • Organogenesis (ORGO) Q1 2024 Earnings Call Transcript

    ORGO earnings call for the period ending March 31, 2024.

    The Motley Fool
  • Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

    CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th.

    GlobeNewswire Inc.
  • Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

    CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted.

    GlobeNewswire Inc.
Dividend data last updated 06/07/2025 19:47:42 UTC